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Purpose: The aim of the study was to evaluate the outcomes of corneal manual 
epithelial debridement (MED) for the treatment of painful bullous keratopathy (BK). 
Methods: In a prospective interventional case series, 15 eyes of 15 consecutive patients 
presenting with painful BK of varying aetiology underwent MED. Patients were followed up at 
10 days, 1 month, 2 months, 3 months and 6 months post procedure. Outcome parameters 
evaluated include numeric rating pain score (NRS), visual acuity (VA), corneal transparency 
and size of corneal bullae. 
Results: The mean NRS was significantly decreased from its baseline value of 7.2 +- 1.7 
at all follow-up visits (p < 0.02). Mean VA and corneal transparency remained stable for the 
duration of the study. In most patients the average size of corneal bullae was initially 
reduced, but returned to baseline by the end of the study. 
Conclusion: MED reduces mean pain scores and temporarily reduces the size of 
corneal bullae in BK. MED may be considered as a simple, low cost alternative for reducing 
pain in patients awaiting corneal transplant. Further studies are required to evaluate MED for 
the treatment of BK and compare outcomes against other palliative treatment options. 
Keywords: Bullous keratopathy, Corneal epithelial debridement 
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Excluding abstract, tables, figures and references: 
• Literature review: 5426 words 
• Manuscript: 2192 words 
Note: the manuscript has been compiled to be as short and concise as possible to improve 
the likelihood of publication. This was advised by the study supervisor and co-author. The 
literature review section has therefore been expanded to make up for the lower word count 















Chapter 1: Introduction and Literature review 
1. Introduction 
A review of the literature on bullous keratopathy with a view to exploring epithelial 
debridement as a novel treatment option. 
1.1 Summary 
Bullous keratopathy (BK) is a painful condition characterised by blisters on the corneal 
surface. The gold standard of treatment is corneal transplant. Unfortunately, transplant may 
be contraindicated or patients may wait long periods prior to transplant.  
Many alternative treatment options which aim to reduce discomfort in patients with BK have 
been described in the literature with mixed outcomes and opinions. 
There is evidence to suggest that epithelial debridement performed during corneal 
crosslinking (CXL), amniotic membrane transplant (AMT) and phototherapeutic keratectomy 
(PTK) plays a significant role in the pain reduction afforded to patients with bullous 
keratopathy. 
Epithelial debridement as a stand-alone procedure for the treatment of painful BK has not 
yet been described in the literature and may be a novel treatment option. 
 
 

















Figure 2: Layers of the cornea 
 
Figure 3: Bullous keratopathy 
2. Objectives of the literature review  
The literature review aims to be comprehensive in its analysis of the literature relevant to BK. 
The core objective of the review is to compare the methods and outcomes of the prevailing 
surgical treatment options for patients who are not suitable for, or are awaiting corneal 
transplant. This sets the scene for introducing the proposed critical research question. The 
review therefore aims to achieve the following:  




• Highlight the prevailing treatment trends, scientific theories, connections and 
contradictions in the literature. 
• Critique relevant arguments by highlighting the main supporting and opposing 
findings. 
• Discuss and compare outcomes of relevant studies. 
• Make comment on the quality of core studies. 
• Attempt to synthesize findings to give guidance on the topic. 
• Uncover scientific gaps and opportunities for further research in the field. 
Through this process the review sheds light on the following questions: 
• What is the magnitude of disease caused by BK? 
• What are the central theories related to the pathology of BK? 
• What treatment practices have evolved over time? 
• What are the demographics across patient study groups? 
• Are the treatment methods standardised? 
• What pain score is used to assess pain in BK? 
• How effective are the various treatment options in reducing pain? 
• What are the strengths and weaknesses associated with each treatment option? 
• What are the qualities which would define the ideal treatment option? 
• Is Manual corneal epithelial debridement (MED) safe? 
• Is there evidence to support the theory that MED may reduce pain in BK? 
• What is the accepted method of MED? 
• What are the gaps in the literature and opportunities for further research 
3. Literature review search strategy 
3.1 Methods 
Data collection 
• The search aimed to be semi-exhaustive in identifying journal articles related to the 
treatment of pain in patients with BK. 
• A systematic review of the literature was conducted by performing a broad search of 
Pubmed and Google scholar.  
• The following keywords, wildcards, brackets and operators were used in various 




1. Keywords: Corneal, Bullous, Keratopathy, Endothelial, Decompensation, Cross 
linking, Phototherapeutic, Keratectomy, Amniotic membrane, Transplant, Stromal 
puncture, Debridement, Polishing, Scraping, Delamination, Erosion. 
2. Operators: AND, OR, NOT. 
3. Brackets: ( ) 
4. Wildcards: * 
• A strategy of preview → overview → inview was employed: 
o Search results were screened for potentially relevant articles. 
o Abstracts of potentially relevant articles were reviewed to assess relevance. 
o Full texts of articles deemed relevant were acquired and bibliographies were 
screened for further potentially relevant articles. 
• This process was repeated until it was felt that a reasonable effort had been made to 
identify all relevant articles. 
Data organisation 
• Articles were grouped thematically as follows:  
o BK 
▪ Pathology  
▪ Management 
• Corneal cross linking 
• Phototherapeutic keratectomy 
• Anterior stromal puncture 
• Amniotic membrane transplant 
• Medical 
• Other 
o Recurrent corneal epithelial erosion syndrome 
o Corneal epithelial debridement 
o Ocular pain 
o Corneal wound healing 
Data evaluation 






Table 2: Data organisation and analysis 
Study     
Validity     
Year     
Journal     
Bias     
Methods     
Study design     
Pain score      
Variables     
Participants     
Aetiology     
Inclusion 
criteria 
    
Exclusion 
criteria 
    
Surgical 
technique 
    
Post op 
treatment 
    
Follow up 
times 
    
Results     
Demographics     
Pre-op pain     
Mean pre CCT     




Table 2 continued: Data organisation and analysis 
Symptom 
duration 
    
     
Pre-op Rx     
Aetiology     
Pain outcome     
VA outcome     
CCT outcome     
Bullae outcome     
Vessels 
outcome 
    
Side-effects / 
Complications 
    
Statistical 
analysis  
    
CCT, Central corneal thickness; VA, Visual acuity 
3.2 Inclusion criteria 
• Type: Peer reviewed journal article. 
• Method: Human, animal, laboratory study. 
• Scope: Minimum 8 patients (core articles). 
3.3 Exclusion criteria 
• Language: No English language version. 
• Availability: Not available on the University of Cape Town (UCT) electronic journal 
database or library. 
• Chronology: Older than 20 years. 




4. Quality criteria 
4.1 Study design 
• Study question or hypothesis 
• Methods 
• Level of evidence 
• Validity 
o Bias and confounding 
o Precision of measurements 
o Effect size and clinical importance 
o External validity 
4.2 Manuscript 
• Peer review 
• Date of publication 
• Author credentials 
• Organisation and structure 
• Analysis, reasoning and conclusions 
• Relevance, scope and context 
• Graphs and illustrations 
• References 
5. Analysis of the literature 
5.1 Pathology of bullous keratopathy  
5.1.1 Introduction 
It is not disputed that the primary pathology causing BK is failure of the corneal endothelial 
pump with subsequent fluid accumulation. If epithelial bullae occur, the term BK is used. 
5.1.2 Visual loss 
Swelling of the corneal stroma causes folds and irregular lamellae in descemet’s membrane. 
This results in light scatter and early loss of Visual acuity (VA).1,2  
Fluid also accumulates in the sub-epithelial space, detaching the epithelium from its 
basement membrane. These fluid filled spaces coalesce to form macrobullae. This 




Following longstanding BK, Sub-epithelial fibrosis (SEF) occurs which causes late 
deterioration in VA.1,2 
5.1.3 Ocular discomfort 
The conventional understanding is that pain in BK is caused by exposure of corneal nerve 
endings. This follows rupture of bullae during microtrauma. Almost all authors agree that this 
is the main mechanism for the ocular discomfort experienced by patients with BK.3,5,7,8 One 
histological study showed that superficial corneal stromal nerves were in fact reduced or 
absent in BK.9 This suggests evidence which conflicts with the above conventional 
understanding. 
Some authors also mention stretching of corneal nerves by epithelial bullae as a mechanism 
for pain. 9This cannot be explained anatomically as corneal nerves do not extend into the 
epithelium, but rather terminate in the superficial stroma.   
5.1.4 Complications 
Chronic BK results in the collection of abnormal collagen structures above the Bowman layer 
which correspond to SEF. Morishige found that SEF was only detected in specimens from 
individuals with a duration of stromal oedema of at least 12 months.1 Longstanding BK also 
predisposes to corneal vascularisation, infection and scarring, which may complicate the 
condition and compromise future surgical outcomes.2,8,10The potential risk of infection in BK 
has been quoted as 4.7%.7 
5.1.5 Aetiology 
The popularity of cataract surgery has made this the most common cause of BK; 
aseudophakic bullous keratopathy (PBK)/aphakic bullous keratopathy (ABK) over the last 30 
years. Corneal graft failure is another important secondary cause of BK. Fuch’s endothelial 
dystrophy (FED) is the most common primary cause of BK.  
Other less common causes referenced in the literature include:  
• Trauma 
• Vitreoretinal surgery 
• Other endothelial dystrophies 
• Congenital anterior segment dysgeneses 
• Refractory glaucoma 
• Laser therapy 




5.2 Treatment of BK 
5.2.1 Overview 
The primary goal of treatment in BK is to alleviate ocular discomfort. The secondary goal is 
to improve visual function. It is generally agreed that keratoplasty (KP) remains the gold 
standard of treatment in patients with good visual potential as it relieves pain and also 
provides visual rehabilitation.2,4,7,8,11,12,13 BK is quoted as the most common indication for KP 
as well as for re-grafting worldwide.3,7,11 
KP might not be indicated for certain patients due to poor visual potential, ocular / systemic 
contra-indications or a lack of corneal transplant facilities. Where KP is indicated and 
resources are available, patients may wait many months before receiving transplant, 
especially in resource poor settings.2,5,6,14 
5.2.2 Alternatives to transplant 
Various alternative medical and surgical treatment options which attempt to alleviate pain 
and improve vision in BK patients have been described. They may be indicated as palliative 
treatment, or as temporising measures for patients awaiting transplant.  
5.2.3 Medical treatment 
Topical Lubricants, hypertonic saline, non-steroidal anti-inflammatory agents (NSAIDS), 
steroids, cycloplegics and bandage contact lens (BCL) may be useful to relieve symptoms in 
early disease. Topical Rho-associated kinase (ROCK) inhibitors is an emerging potential 
treatment option. Advanced disease usually requires surgical intervention.2,9,15,16 
5.2.3.1 Lubricants, cycloplegics, steroids and NSAIDS 
Although these are often quoted as a treatment option, there are no studies quantifying the 
effect which they have on pain or VA in patients with BK. There is also concern over 
potential side-effects of steroids [Delayed epithelial healing, Infective keratitis (IK)] and 
NSAIDS (Corneal melt).17 
5.2.3.2 Hyperosmotic solutions 
Results of a prospective comparative study of 70 eyes of 55 patients showed that hypertonic 
saline was only useful in early disease for improving VA and reducing central corneal 
thickness (CCT), but not in more advanced disease. Hypertonic saline is simple to use, but 
not all patients can tolerate the drops due to stinging. 2 




BCL has been shown to improve corneal epithelial healing.17,18 One prospective comparative 
study showed significantly improved comfort scores in BK patients using 3 different types of 
BCL.16 
Unfortunately BCL requires 2 weekly follow up for lens exchange, is known to be the most 
significant risk factor for IK and may cause corneal vascularisation.10,19 
5.2.4 Surgical treatment 
Multiple surgical treatment options were described in the literature with varying frequency 
and differing levels of evidence. 
Frequently described treatment options with good levels of evidence, in chronological order, 
include:  
1) Phototherapeutic keratectomy (PTK) 10,12, 23 
2) Amniotic membrane transplant (AMT) 4, 7, 8, 9, 13, 23  
3) Anterior stromal puncture (ASP) 9,11,22  
4) Corneal crosslinking (CXL) 5, 6, 24, 25   
Less common treatment options mentioned in the literature 2,4,10,12,20,21,22, in alphabetical 
order, include:  
1) Annular keratotomy 
2) Autologous perichondrium transplantation 
3) Corneal surface thermal or laser cautery 
4) Cultured endothelial cell injection 
5) Diamond burr polishing 
6) Enucleation or evisceration 
7) Epikeratophakia 
8) Gunderson flap 
9) Intrastromal silicone oil/hydrogel lens insertion 
10) Posterior corneal cryopexy 
11) Retrobulbar alcohol 
All the commonly used treatment modalities aim to reduce the presence of bullae by one of 
the following mechanisms: 
1) Allowing a fresh layer of epithelium to cover the corneal surface: CXL, PTK, AMT 
2) Increasing adhesion between the epithelium and the underlying basement 




3) Preventing corneal stromal swelling: CXL 
5.3 Analysis of the core literature 
Table 3: Core studies by intervention and first author 
PTK AMT ASP CXL 
Lin12 Chawla23 Gomes 22 Ghanem5 
Maini10 Pires4 Sridhar 11 Gharaee24 
Chawla23 Espana7 Paris9 Arora6 
 Chansanti8  Sharma25 
 Georgiadis13   
 Paris9   
AMT, Amniotic membrane transplant; ASP, Anterior stromal puncture; CXL, Corneal collagen cross-
linking; PTK, Phototherapeutic keratectomy 
5.3.1 Are patients comparable across studies? 
5.3.1.1 Demographics 
The mean age of study patients ranged from 50 to 83 and the average mean age was 66 
years of age. There were no children included in any studies. All studies included both men 
and women and there were roughly equal numbers of each in total. Differences in age or sex 
which may have been present are unlikely to have affected study outcomes. 
Racial demographics were not recorded by any studies. This may be important to note due 
to racial differences in wound healing response.26,27 
5.3.1.2 Inclusion and exclusion criteria 
VISUAL POTENTIAL 
In the studies related to PTK and AMT only patients with poor visual potential were included 
in the study. In the ASP studies Gomes22 and Paris9 also included patients with good visual 
potential. It appears all the patients included in the CXL studies had good visual potential, 
although Sharma25 does not make specific mention of this.  
Patients with poor visual potential often have a history of glaucoma, trauma, diabetic 
retinopathy or other ocular disease which may affect study outcomes. Ideally sub-analysis 
should be performed between those with and without visual potential. Unfortunately, this is 
usually not possible due to limited study participant numbers. 




Elevated intraocular pressure may worsen the symptoms of BK. These patients should 
therefore be excluded or analysed separately. This confounding factor was unfortunately 
seriously under reported, with only the studies by Arora6 and Paris9 citing this in their 
exclusion criteria. 
5.3.1.3 Aetiology of BK 
In FED the epithelial basement membrane has been shown to display dystrophic features. 
28,29 In graft failure, there may be issues with adhesion of the host epithelium to the 
underlying donor stroma. Both these factors may negatively affect epithelial adhesion. 
PBK was the most common cause of BK across the studies. Studies by Maini10, Chawla23, 
Ghanem5, Arora6 and Sharma25 included only patients with PBK. Other studies included 
patients with BK of varying aetiologies. Failed graft was a common cause of BK in the PTK 
studies and in the study by Gharaee24. Espana7, Paris9 and Sridhar11 were the only studies 
which included patients with FED. 
Unfortunately, there was no sub-analysis performed between patients with differing 
aetiologies in BK, thus comment cannot be made as to whether there were differences in 
outcome. 
5.3.1.4 Severity and duration of BK 
CCT is a good indicator of the severity of BK whereas duration of symptoms has been 
shown to be an indicator of the risk for sub-epithelial fibrosis30. Both have been shown to 
affect treatment outcomes. These are therefore important clinical variables to indicate 
whether outcomes between patient study groups can be compared. 
Unfortunately, pre-intervention CCT was only mentioned in 8 of the 16 studies and duration 
of symptoms in 4. In some patients CCT was un-recordable due to the severity of corneal 
oedema. This may result in a falsely low mean CCT. A normal CCT is 550 µm, the mean 
CCT of the study participants ranged between 725-872 µm. This shows that there was 









Table 4: Pre-intervention CCT and duration of symptoms 
Study Intervention CCT Mean duration of BK 
Maini10 PTK Mean 762 µm (range 588–969 µm) NA 
Chawla23 PTK+AMT Mean 730 µm (range 610–922 µm) 17 months (range 3–48) 
Paris9 AMT+ASP Mean 814 µm (range 463–1725 µm) 27 months (range 2–96) 
Pires4 AMT  NA 23 months (range 0–240) 
Espana7 AMT NA 12 months (range 1–36) 
Chansanti8 AMT NA 16 months (range 5–24) 
Gomes22 ASP Mean 854 µm (range 672–1029 µm) NA 
Ghanem5 CXL Mean 747 µm (range 630–837 µm) NA 
Gharaee24 CXL Mean 872 µm (range 710–1040 µm) NA 
Arora6 CXL Mean 813 µm (range unknown) NA 
Sharma25 CXL Mean 725 µm (range 650–800 µm) NA 
AMT, Amniotic membrane transplant; ASP, Anterior stromal puncture; BK, Bullous keratopathy; CCT, 
Central corneal thickness; CXL, Corneal collagen cross-linking; NA. Not analysed; PTK, 
Phototherapeutic keratectomy 
The mean duration of symptoms varied between 12 and 27 months. There was a large inter-
individual range of between 0 and 240 months. Morishige showed that SEF was only present 
on histology after a symptom duration of 12 months or more. The effect which SEF has on 
treatment outcomes has not been evaluated. It may well play an important role. 
These results show that there is a large variation in the mean severity and duration of BK 
which makes it difficult to directly compare study outcomes. 
5.3.2 Are the study methods standardised? 
5.3.2.1 Study design and scope 
All studies consisted of prospective interventional clinical trials except for the studies by 
Espana,7 Sridhar11 and Sharma25 which were performed as retrospective reviews and 
therefore may constitute lower levels of scientific evidence. There were only two randomised 
comparative clinical trials. The first by Chawla23 compared outcomes between AMT and PTK 




The number of patients in each study varied between 8 and 85. 
 
Figure 4: Number of study participants 
5.3.2.2 Medical treatment 
Only 4 studies made note of what medical treatment patients were using prior to 
intervention. These included artificial tears, lubricants, hypertonic saline solution, bandage 
contact lens.4,6,8,13 Unfortunately, it was not stated whether this treatment was continued or 
discontinued following surgical intervention.  
The medical treatment given to patients following surgical intervention also varied 
significantly both within and between studies. Of importance is the inconsistent use of, and 
duration of treatment with, BCL’s. Some authors inserted BCL for patients only until corneal 
epithelialisation had occurred (Chawla,23 Gharaee24) whereas Lin exchanged the BCL every 
2–3 weeks for a period of 3 months. Pires4 inserted a BCL in 62% of patients, and not in the 
remaining 38%.12 
Medical treatment is a confounding factor which may skew the results and therefore needs 
to be accurately controlled and recorded. The following are suggested guidelines which may 
assist in minimising this bias: 
• Medical treatment being used prior to intervention should either be stopped for at 
least one month prior to intervention or should be continued afterwards.  
• New medical treatment given post intervention should be kept to a minimum as 
required and should stopped as soon as possible.  
• Any outcomes recorded while medical treatment is still being administered should be 
noted as such.  





















5.3.2.3 Surgical intervention method 
PTK: In all studies, manual corneal epithelial debridement was performed under topical 
anaesthetic which was followed by laser keratectomy. All the studies varied in terms of the 
size of central and peripheral ablation areas created and there was also no standard depth 
to which the stroma was ablated.  
AMT: All studies performed manual epithelial debridement followed by AMT using fresh 
frozen amniotic membrane (AM). All authors attached the AM with the basement membrane 
side up. The most common method of applying the AM was using the “inlay” method. Here 
the AM is sutured onto the cornea over the epithelial defect. This was used by in five of the 
six studies. In three studies the AM was sutured directly onto the cornea whereas the other 
two sutured the AM into lamellar pockets created in the peripheral cornea. Espana7 further 
used a second AM graft sutured over the first. Georgiadis13 used a novel method whereby 
the AM was sutured onto the limbal conjunctiva thereby forming an epithelial “overlay” rather 
than an “inlay”.  
ASP: Gomes22 and Paris9 applied roughly 100 punctures using a 25G needle whereas 
Sridhar11 used 200 punctures using a 26G needle. 
CXL: All studies used the standard Dresden protocol which consists of: 
1. Manual corneal epithelial debridement following topical anaesthetic. 
2. Riboflavin (0.1%) eye drops applied repeatedly for 30 min.  
3. Corneal cross-linking through application of UVA (370 nm, 3 mW/cm2) for 30min 
while continuing to apply riboflavin drops. 
There was variation in the surgical technique used in all the intervention methods besides for 
CXL, where set guidelines were followed. Ideally all the procedures should be standardised 
so that outcomes are not affected by variation in surgical technique. 
5.3.2.4 Visual acuity recording 
All authors used the Snellen VA grading system. Arora6 and Sharma25 later converted this to 
LogMAR for statistical analysis.  
Visual acuity before and after intervention was recorded in all studies besides Maini10. 
Chawla,23 Gomes22 and Paris9 commented on, but did not quantify the change in VA. Pires,4 
Espana7 and Sridhar11 only quantified the VA’s of patients in whom vision had improved. All 
the CXL studies quantified the pre and post intervention VA’s. They further calculated 




Accurately recorded visual acuities before and after intervention are important for evaluating 
the effect an intervention has on this clinically relevant outcome. Unfortunately, most patients 
with advanced BK have very low VA and changes in VA are more difficult to quantify. A tool 
for accurately measuring and comparing visual function in patients with severe visual loss 
would be useful in these patients. 
5.3.2.5 Pain score used 
The methods used to qualify and quantify pain were poorly standardised which makes it 
difficult to compare outcomes between studies. The pain scoring methods which were used 
include:  
Multivariate pain scores 
• Qualitative ocular symptom questionnaire: Espana,7 Gharaee24 
o Presence of pain, photophobia, tearing, and foreign-body sensation recorded. 
• Quantitative ocular symptom scale/questionnaire: 
o Gomes:22 Questionnaire with foreign-body sensation (0 to 3), pain intensity (0 
to 3), photophobia (0 to 3), and insomnia related to pain. 
o Chawla:23 Ocular symptom scale: Asymptomatic (0), minimal (1), mild (2), 
moderate (3), severe (4). 
• Pain duration score: Paris9 
o Total duration and the duration of the worst episode of pain experienced by 
the patient was recorded in the preceding month was recorded as <30 min, 
≤4 h or >4 h. 
Univariate pain scores 
• Binomial description of ocular pain as worse or better: Lin,12 Maini,10 Pires4, 
Chansanti,8 Srhidar. 11  
• Numeric rating score: Paris,9 Sharma25  
o Patients asked to score the maximum intensity of pain experienced in the 
preceding 1 month period on a scale of 1–10 (1=minimal pain and 
10=unbearable pain).  
• Visual analog pain score (VAS): Ghanem,5 Arora6 
o Patients asked to mark on a line, from 1 to 10, the point they believe 
represents their perception of pain. The VAS score was determined by 
measuring from the left-hand end of the line to the point marked by the patient 




Ocular symptom questionnaires are important for qualitative data capturing the complexity of 
patient discomfort and fluctuations in symptoms 31. They unfortunately make it difficult to 
compare study outcomes and to evaluate the statistical significance of changes in symptoms 
following an intervention.  
To determine the magnitude of pain relief afforded by an intervention quantitative pain 
scores are preferable. The numeric rating pain score (NRS) and VAS are both valid, easy to 
administer and have been shown to be highly correlated with one another. The VAS has 
been shown to have superior sensitivity to changes in pain score whereas the NRS has 
been shown to be have high test-retest reliability in patients with chronic pain conditions. The 
verbal numeric pain score has the advantages of being simpler for patients to perform and 
can be recorded telephonically.32 
5.3.3 Study outcomes  
5.3.3.1 Pain 
For the PTK, AMT and ASP studies which used binomial outcomes or questionnaires, 
outcomes at the end of the study can be grouped into one of three categories: “No pain”, 
“Significantly reduced pain” or “Pain similar to baseline”. “Significantly reduced pain” refers to 
a reduction in pain which study participants subjectively considered as “Significant”.  
Table 5: Pain outcomes and mean duration of follow up after PTK, AMT and ASP 










Lin12 PTK 88% NA NA 11 months 
Maini10 PTK NA 73% 22% 8 months 
Chawla23 PTK 90% 10% 0% 8 months 
Chawla23 AMT 80% 20% 0% 8 months 
Pires4 AMT 90% 6% 4% 8 months 
Espana7 AMT 73% 22% NA 6 months 




Table 5 continued: Pain outcomes and mean duration of follow up after PTK, AMT and 
ASP 
Georgiadis13 AMT 88% 22% 0% 21 months 
Gomes22 ASP 64% 7% 29% 5.5 months 
Sridhar11 ASP 71% 29% 0% 9.5 months 
AMT, Amniotic membrane transplant; ASP, Anterior stromal puncture; NA, Not analysed; PTK, 
Phototherapeutic keratectomy 
All studies showed that the greatest proportion of participants either had no pain or a 
significant reduction in pain at the end of the study. Only Maini10 and Gomes22 report a 
significant number of patients with pain outcomes similar to baseline following PTK and ASP 
respectively. Unfortunately, there were large differences in the duration of follow up which 
may have affected outcomes as pain scores are likely to change over time. 
The CXL studies assessed pain outcomes quantitatively using visual analog and verbal 
numeric pain scores. There was also better standardisation of follow up intervals. These 
factors allow for better comparison of CXL outcomes when compared with other studies. 
 
Figure 5: Changes in pain score with time following CXL 
If a drop in pain score of 2 or more is considered as significant then the reduction in pain at 











Baseline 1 month 2 months 3 months 6 months
Change in pain score over time




showed a late trend towards a return to baseline in all studies except for pain following ASP 
in the study by Paris.9  
5.3.3.2 Visual acuity 
For the PTK, AMT and ASP studies outcomes at the end of the study can be grouped into 
one of three categories: “VA unchanged”, “VA improved” or “VA decreased”.  
Table 6: VA outcomes and mean duration of follow up after PTK, AMT and ASP 









Lin12 PTK 75% 25% 0%  11 months 
Chawla23 PTK 85% 15% 0%  8 months 
Chawla23 AMT 92% 8% 0%  8 months 
Pires4 AMT 76% 18% 6%  8 months 
Espana7 AMT 77%  17% 6%  6 months 
Georgiadis13 AMT 79%  17% 4%  21 months 
Sridhar11 ASP 32% 25% 43%  9.5 months 
AMT, Amniotic membrane transplant; ASP, Anterior stromal puncture; PTK, Phototherapeutic 
keratectomy; VA, Visual acuity 
The number of patients who showed a significant improvement in their VA was similar 
across the various interventions and on average 18% of patients had improvement. 43% of 
participants had significantly decreased VA following ASP in the study by Sridhar11. This is 
likely due to the corneal scarring which is a well described side effect of ASP. 
For the CXL studies change in VA over time can be classified as either “Statistically 








Table 7: VA changes with time following CXL 
Study Intervention VA at 1-2 
weeks 
VA at 1 
month 
 
VA at 3 
months 
VA at 6 
months 
Ghanem5 CXL NA Significant 
improvement 
NA No change 
Gharaee24 CXL NA NA NA No change 




No change NA 
Sharma25 CXL Significant 
improvement 
No change No change No change 
CXL, Corneal collagen cross-linking; NA. Not analysed; VA, Visual acuity 
Although some studies showed significant improvement in VA during the first month after 
intervention this was not sustained and no significant change in VA was seen by 3 months. 
5.3.3.3 Recurrence of bullae 
All studies showed some recurrence of bullae although there was wide variation from 10% 
following AMT to 79% following CXL.  
There appeared to be a trend towards recurrence of bullae over time in the study by 
Sharma25 where bullae were seen in 6% of participants at 1 month, 24% at 3 months, and 
44% at 6 months after CXL. 
Table 8: Recurrence of bullae and duration of follow up 
Study Intervention Recurrence of bullae 
 
Duration of follow up 
Lin12 PTK 13%  11 months 




Table 8 continued: Recurrence of bullae and duration of follow up 
Chansanti8 AMT 41%  14 months 
Pires4 AMT 10%  8 months 
Paris9 AMT 22%  6 months 
Paris9 ASP 38%  6months 
Sridhar11 ASP 43%  9.5 months 
Ghanem5 CXL 79%  6 months 
Sharma25 CXL 44%  6 months 
AMT, Amniotic membrane transplant; ASP, Anterior stromal puncture; CXL, Corneal collagen cross-
linking; PTK, Phototherapeutic keratectomy 
 
5.3.3.4 Other outcomes 
Corneal clarity scores were only used in the CXL studies. A similar scoring system was used 
in 3 of the CXL studies.  Corneal clarity was graded from 1 to 4 by assessing the clarity of 
the iris details as viewed through the cornea. Arora6 used an alternative grading system from 
1 to 4 which graded the clarity by looking for features of progressive BK such as stromal 
oedema, bullae and fibrosis. 
Anterior segment photographs were used by Espana7 and Paris.9 Photographs were used to 
assess the number and size of corneal bullae which may give an objective indication of 
disease severity. Photographs also allowed the degree of vascularisation of the cornea to be 
assessed which is important as vascularisation may affect KP outcomes. 
Corneal sensitivity readings were recorded by Paris9 and Gomes.22 Both used a Cochet and  
Bonnet aesthesiometer. 
5.3.3.5 Severe complications 
3 incidences of IK were reported. One following PTK in the study by Lin12 and 2 following 




5.4 Analysis of the literature on MED 
5.4.1 Arguments for and against MED as a method of treating BK 
The results of CXL are not full explained by the process of stromal cross linking. Although 
CXL has proven to provide increased resistance to stromal swelling,33 it is not clear whether 
this translates into a reduced drive towards corneal epithelial oedema.  
MED has been used effectively in the treatment of Recurrent corneal erosion syndrome 
(RCE) by increasing epithelial adhesion. Studies showed that interventions which also 
remove the underlying basement membrane such as Diamond burr polishing or PTK are 
superior to MED alonein the treatment of RCE.19,31,32 BK differs to RCE in that the basement 
membrane is not inherently abnormal and therefore its removal is likely not necessary in BK, 
as it is in RCE. 
In the study by Sharma25 he comments: “Epithelial debridement may itself be causing a 
temporary effect on corneal thickness and other study variables such as pain score and 
BCVA”. 34 
5.4.2 Method of MED: Manual vs Alcohol assisted 
The literature suggests that Alcohol delamination of the epithelium for the treatment of RCE 
may be superior to manual debridement.34,35 There are however grounds for concern over 
the potentially toxic effects of alcohol on the endothelium.36 
Alcohol delamination has not yet been described as part of the management of BK whereas 
manual debridement is well described as part of AMT, PTK, and CXL. 
The evidence therefore suggests that manual debridement may be the safer method of MED 
in BK. 
5.5 Summary of the literature 
Keratoplasty remains the gold standard of treatment for BK. Anterior stromal puncture, AMT, 
PTK or CXL should be considered for the management of painful BK in patients with poor 
visual potential or without access to early keratoplasty.  
ASP, AMT and PTK appear to provide long term pain relief. There was much however much 
variation in study methodology and the pain scores used do not allow for accurate cross 
analysis. This brings the study findings into question. CXL studies were better standardised 
and treatment was shown to provide short-term pain relief. ASP was shown to cause corneal 




There is a feeling amongst many authors that there is still a need for a safe, cheap and 
effective treatment option for relieving pain in patients with bullous keratopathy. The 
literature suggests that corneal epithelial debridement may fulfil this requirement and 
indicates a need for well-constructed studies which evaluate this possibility further. 
6. Identification of gaps and opportunities for further 
research 
6.1 Gaps 
1. There is a lack of long term clinical trials which compare the safety and efficacy of 
available treatment options. 
2. Standardised surgical methods are required for ASP, PTK and AMT. 
3. There is a need for a grading system to classify the severity of corneal bullae in BK. 
6.2 Potential future research questions / studies 
1. Is MED alone effective for reducing pain in BK? 
2. MED vs CXL/PTK/AMT. 
3. What is the best pain score to use when assessing patients with BK. 
4. Does the number/area of corneal bullae correlate with pain score. 
5. Does the CCT correlate with pain score. 
6. Does lowering normal intraocular pressure reduce pain score. 
7. The effect of surgical treatments on subsequent keratoplasty. 
8. ROCK inhibitors and cultivated endothelial cells for the treatment of bullous 
keratopathy not caused by FED. 
9. Alcohol debrided vs mechanically debrided MED in BK. 
10. Histopathological study: Does epithelial-on CXL reduce fluid accumulation in the sub-
epithelial space or only in the stroma. 
11. UV exposure and safety threshold when applied to sick endothelium in BK. 
7. Proposed research 
7.1 Introduction 
There is a gap in the literature with regards to the safety and efficacy of MED for the 
treatment of BK and this comprises the critical research question. This dissertation makes a 
meaningful contribution to knowledge in the field by establishing a new line of theory that 




provide early evidence and statistical data which pave the way for further research in the 
field.  
7.2 Primary research aims 
•  To evaluate the safety and efficacy of MED in the management of pain in patients 
suffering from symptomatic bullous keratopathy. 
• To evaluate the effect of MED on visual acuity, number of corneal bullae, corneal 
transparency and central corneal thickness. 
7.3 Secondary research aims 
• Compare MED outcomes with those of other palliative treatment options. 
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Chapter 2: Publication-ready manuscript 
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McClunan DB, Du Toit N, Pollock TP 
Introduction 
Bullous keratopathy (BK) is a disabling condition caused by failure of the corneal endothelial 
pump function. Stromal and epithelial oedema occurs in early disease. In later disease, sub-
epithelial fluid collections produce corneal bullae. These bullae are the primary cause of 
discomfort and the characteristic features of BK 1-4. In longstanding disease sub-epithelial 
fibrosis replaces the fluid-filled spaces5.  
The gold standard of treatment is corneal transplant, which offers both pain relief and visual 
rehabilitation. Unfortunately, patients may not be suitable for transplant or may not have 
access to transplant facilities. Many palliative surgical procedures, which aim to reduce pain 
in BK patients, have been described. Three of the four most widely studied interventions 
corneal crosslinking (CXL), amniotic membrane transplant (AMT), phototherapeutic 
keratectomy (PTK) and anterior stromal puncture (ASP), employ manual corneal epithelial 
debridement (MED) as part of the surgical procedure.  
MED has been used safely and effectively in the treatment of recurrent corneal erosion 
syndrome6 and has been shown to increase epithelial adherence to the underlying 
Bowman’s membrane.7 It follows that MED performed in the presence of BK may prevent 
fluid influx into the sub-epithelial space and therefore limit the formation of painful bullae. 
This suggests that the MED performed as part of CXL, AMT and PTK may play a significant 
role in the pain reduction these interventions afford to patients with BK.8 
Materials and methods 
Consecutive patients who presented to the Groote Schuur Hospital Eye Clinic with painful 
BK between May and December 2016 were considered for the study. Vulnerable patients, 
patients not willing to consent and patients with significant ocular surface disease or 
intraocular pressures above 30 mmHg were excluded.  
Patients included in the study underwent a complete ophthalmological history and 
examination prior to the procedure. The aetiology of BK, duration and severity of symptoms 
and current medical treatment were recorded. Pain score was evaluated using the verbal 




ocular pain on a scale of 0 to 10 according to subjective pain perception. 0 representing no 
pain and 10 the worst pain imaginable.  
Anthropometric parameters evaluated at baseline included Snellen visual acuity (VA), central 
corneal thickness (CCT) measured by ultrasonic pachymetry (Alcon OcuScan), average size 
of corneal bullae and corneal transparency.  
Average size of corneal bullae was assessed using anterior segment photographs taken 
post instillation of fluorescein. Corneal transparency was graded according to a known 
system used in the CXL studies by Ghanem and Sharma et al. 4,8 
0 – clear cornea 
1 – mild oedema with minimal loss of transparency 
2 – moderate oedema with iris details visible 
3 – severe oedema with iris details obscured  
4 – opaque cornea with no iris details visible 
In patients with bilateral disease MED was performed in the eye with the highest pain score. 
The procedure was performed under sterile conditions in the minor procedures room of the 
Groote Schuur Hospital Eye Clinic, as follows: 
1. Benoxinate topical anaesthetic drop instilled every minute for 5 minutes. 
2. Epithelial area to be debrided marked using a 10 mm circular trephine. 
3. Epithelium manually debrided with an ophthalmic spoon. 
4. Debris cleaned from basement membrane using a cotton bud. 
5. Bandage contact lens (BCL) inserted. 
 




Oral analgesia and a topical antibiotic drop (Ofloxacin “OCTIN”, Cipla, Mumbai, India) qid 
were prescribed. Patients were followed up 10 days later where BCL was removed and a 
steroid / antibiotic combination drop (Dexamethasone / Chloramphenicol “SPERSADEX 
COMP”, Novartis, Basel, Switzerland) was prescribed qid for a period of 1 week. Patients 
were followed up again at 1 month, 2 months, 3 months and 6 months post procedure. At 
each follow-up visit patients underwent an ophthalmic examination with repeat measurement 
of the study parameters and documentation of any complications. The average size of 
corneal bullae was assessed as being unchanged, reduced or increased, as agreed by the 
authors.  
Pre-existing topical treatment, such as lubricants or hypertonic saline, were continued 
throughout the study period.  
The study methodology complies with the principles described in the declaration of Helsinki 
and was approved by the University of Cape Town Human Research Ethics Committee. 
Statistical analysis 
Pre-operative values were used as controls and outcomes were compared against these 
baseline values at each follow up visit. Quantitative data are expressed as mean +- standard 
deviation. Qualitative data are represented as a proportion or percentage. Data analysis was 
performed using IBM SPSS version 24. Normality was assessed using the Shapiro-Wilk test. 
Pain score and corneal transparency were analysed using the paired t-test. Associations of 
pain and corneal transparency scores over time were assessed using Pearson correlation. 
VA was analysed using the chi-squared test. 
Results 
A total of 15 eyes of 15 patients were included in the study. The average age of participants 
was 63.3 years +- 12.2 (range, 34-80 years). There were 4 men and 11 women. BK was due 
to trauma in 1 patient, graft failure in 2 patients, Fuch’s endothelial dystrophy in 2 patients 
and pseudophakic BK in the remaining 10 patients. The average duration of disease was 24 
months +- 33 (range, 2-136 months). 
The average pain score at time of presentation was 7.2 +- 1.7 (range, 5-10). Average pain 
scores were significantly decreased at all follow up visits as follows: Day 10 = 4.4 +- 2.6 
(range, 1.5-9.5, p = 0.0015); 1 month = 3.5 +- 2.4 (range, 1-9, p = 0.0004); 2 months = 3.5 +- 
2.4 (range, 1-8, p = 0.0016); 3 months = 3.4 +- 2.1 (range, 1-8, p = 0.0003); and 6 months = 
3.8 +- 2.4 (range, 1-7.5, p = 0.0005). There was 1 patient lost to follow up after 1 month.  A 




after 3 months due to worsening ocular pain which required rescue treatment with hypertonic 
saline, lubricants, oral analgesia and BCL insertion. One patient excluded from the study 
defaulted her follow-up visit. She subsequently presented with an IK complicated by 
endophthalmitis after wearing her BCL continuously for 8 weeks. The other patient excluded 
from the study went on to receive penetrating keratoplasty 
 
FIGURE 2: Change in NRS pain score over time following MED in BK 
The average CCT was 667 µm on presentation, but this parameter was only recordable in 7 
of the 15 patients. CCT was therefore excluded from further analysis.  
The average corneal transparency at presentation was 2.5 +- 0.5 (range, 2-3). Baseline 
transparency improved in 2 patients and decreased in 1 patient at all visits following MED. 
There was no significant change in average corneal transparency throughout the study (p < 
0.02).  
The VA at presentation was CF in 9 patients, HM in 3 patients and NLP in 3 patients. VA 
improved from HM to CF at all follow-up visits in 2 patients. VA decreased from HM to NLP 
in one patient at the 3 months follow-up visit. Central retinal artery occlusion was suspected 
as the cause of visual loss due to the presence of new vessels on the iris. There was no 
significant change in average VA found during the study (p < 0.005). 
At 1 month follow up, the average size of corneal bullae was reduced in 75% of patients, 
unchanged in 17% and increased in 8% of patients when compared with baseline. By 6 
months however, the size of corneal bullae remained reduced in only 30% of patients and 

















        
FIGURE 3: Anterior segment photography showing the size of corneal bullae in a patient at 
baseline, 1 months and 6 months after MED. Bullae appear as discrete or coalescent dark 
mounds surrounded by lakes of fluorescein. 
No persistent epithelial defects were noted. One patient presented with a scleritis type 
picture at 2 weeks post debridement. The pain responded well to a short course of oral 
prednisone. No other complications were noted.  
Discussion 
CXL4,8,9,10, AMT2,3,11-14 and PTK14,15,16 for the palliative treatment of BK have been relatively 
well described. The literature suggests that they are all effective options for reducing pain in 
patients with BK. Unfortunately, these procedures are time-consuming and expensive. CXL, 
AMT and PTK all employ MED as the initial step in the surgical procedure. MED is simple, 
inexpensive and has been used safely and effectively for reducing pain in recurrent corneal 
erosion syndrome. There are however, no other studies which evaluate MED as a means for 
reducing pain in BK and no studies comparing MED vs CXL, AMT or PTK for the treatment 
of BK.  
In this study, we found that MED was effective in reducing the mean pain score over a 
period of 6 months in patients with BK. Subjective numeric pain scores were also used in the 






FIGURE 4: Comparison of pain score outcomes following MED, CXL and AMT for BK 
All studies showed early improvement in pain scores with a late trend towards regression. 
AMT appears to be more effective than both CXL and MED in reducing pain scores beyond 
2 months. A confounding factor in our study was that 2 patients, whose pain scores 
remained high at the 2 and 3 months follow-up visits, were excluded from future statistical 
analysis due to the initiation of rescue treatment. The pain scores at 3 and 6 months may 
therefore be falsely low. One patient, who had been excluded from the study, developed IK 
after failing to replace her BCL. This highlights the fact that contact lens wear remains the 
most significant risk factor for developing IK.17 For this reason, BCL should be used with 
caution in the treatment of BK. 
In other studies, numerical pain scores were not used. The severity of pain experienced by 
patients at the end of the study was reported broadly, as either “no pain”, “significantly less 
pain” or “pain like baseline”. 
The PTK and AMT studies had a longer follow up than the CXL studies. They report that the 
greatest proportion of participants either had no pain, or a significant reduction in pain at the 
end of the study. It therefore appears that PTK and AMT may be more effective than CXL 
and MED for reducing pain over longer periods of time. Long term comparative studies are 
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TABLE 1: Comparison of pain outcomes following PTK and AMT for BK.  
Study author Intervention Pain free  
 
Significantly 





Lin16 PTK 88% NA NA 11 months 
Maini15 PTK NA 73% 22% 8 months 
Chawla14 PTK 90% 10% 0% 8 months 
Chawla14 AMT 80% 20% 0% 8 months 
Pires12 AMT 90% 6% 4% 8 months 
Espana2 AMT 73% 22% NA 6 months 
Chansanti3 AMT NA 82% NA 14 months 
Georgiadis11 AMT 88% 22% 0% 21 months 
AMT, Amniotic membrane transplant; NA, Not analysed; PTK, Phototherapeutic keratectomy 
 
The onset of sub-epithelial fibrosis in BK has been associated with at least 12 months history 
of symptoms.5 The mean duration of symptoms experienced by our patients prior to 




FIGURE 5: Duration of BK symptoms in months prior to MED, AMT and PTK  
CCT was unrecordable in 8 of our study patients. In these patients, the odds were 4 times 
higher that they had a symptom duration of 12 months or more compared with patients 
where CCT was recordable. Our mean CCT may therefore be falsely low because of missing 












data from patients with advanced disease. Sub-epithelial fibrosis may have contributed to 
our difficulty in obtaining CCT measurements in these patients.  
MED did not significantly affect VA or corneal transparency in our study group. However, our 
small study size reduces the reliability of the chi-squared test. The lack of corneal opacity 
following MED is desirable because eyes remain suitable for endothelial keratoplasty.  
 
FIGURE 6: Number of participants in studies evaluating MED, CXL, AMT and PTK for BK 
The size of corneal bullae, although reduced at the 1 month follow up in a large percentage 
of patients, returned to baseline size by 6 months in most patients. The correlation between 
size of corneal bullae and patient pain score has not been evaluated in the literature. There 
is also no grading system described which quantifies the severity of corneal bullae. These 
could be useful tools for statistical analysis, but larger studies are required to determine 
these parameters. 
MED is fast, simple and inexpensive to perform. In our study MED was found to be safe and 
effective in reducing subjective pain scores over a period of 6 months. MED also temporarily 
reduced the size of corneal bullae in most patients and shows promise as a method for 
treating patients who are not suitable for, or are awaiting transplant. However, our study 
numbers were small and there appeared to be a tendency towards regression in pain scores 
by 6 months. Larger and more long-term studies are required to further evaluate MED and 
compare it against other procedures used in the palliative management of BK.  
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Appendix A: Informed consent 
 
Why is this study being done? 
• We would like to study whether a procedure called “Epithelial debridement”, which is 
helpful in another eye condition similar to yours, will work for your condition as well 
• We want to test whether the procedure will decrease the pain you are experiencing 
• We need to make sure the procedure is safe 
Why are you being asked to take part? 
• You have an eye condition called “Bullous keratopathy”. This is when blisters form on 
the front of the eye because of swelling in this area. These blisters cause the pain 




How many people will take part in the study? 
• We aim to have at least 15 people take part 
How long will the study last? 
• The study will be done over a period of one year from 1 May 2016 to 31 March 2017. 
• You will be followed up for six months after the procedure has been done. 
• At the end of these six months you and the doctor will discuss how your condition is 




What do we do to decide if you are eligible to be take part? 
• Doctor will make sure that you do have the condition known as Bullous keratopathy 
• Doctor will make sure you don’t have signs of other eye conditions which could put 
you at higher risk of having problems from the procedure 
• Doctor will discuss the study with you and make sure you are happy to take part 
Do you have to take part in the study? 
• No. It is completely up to you whether you would like to take part in the study 
• If you decide not to take part you will be treated as usual with eye drops 
• You can decide to pull out of the study at any point 
What will happen if you decide to take part in the study? 
• After discussing any questions you have with the doctor you will need to sign this 
form to show that you have agreed to take part 
• The procedure will be done on the earliest day that suits you and where doctor is 
available 
• Doctor will record some information regarding your condition and also take photos of 
your eye 
• After this the procedure will be done in the minor procedures room at the eye clinic 
• You will need to return to the Groote Schuur eye clinic for check-ups at ten days, one 
month, two months, three months and six months after the procedure. Doctor will 
again record some information and take photos of  your eye during these check ups 
What does the procedure involve? 
• The doctor will put drops in your eye for 5 minutes which will kill any germs in your 
eye and numb the eye so you won’t feel pain during the procedure. 
• Doctor will use an instrument to keep your eyelids open for you and then will rinse 
the eye clean. 
• You will need to lie down on a bed and keep still for about five minutes while the 
doctor is working on your eye through a microscope 
• The blisters will then be cleaned off the eye using a blunt spoon and a small sponge 
• The eye will be rinsed again 
• A soft contact lens will be placed on your eye to protect it while it is healing 




• Doctor will explain that you should come to the Groote Schuur emergency area 
urgently if you experience any Redness, Sensitivity to the light, decreasing Vision or 
worsening Pain (RSVP) 
• You will go to the pharmacy to collect some pain tablets and drops which you will 
need to put in the eye four times a day 
• You can expect the eye to become painful about thirty minutes after the procedure 
and this could last for around one week 
• It is important that you use the drops as prescribed and keep the eye clean for the 
first week after the procedure. This means no swimming. You can still bath or shower 
but you should avoid getting water into the eye. Don’t rub the eye or put your fingers 
into your eye. If the contact lens falls out, don’t put it back in. Keep it in a container or 
piece of clean tissue paper and contact the doctor. 
What are the benefits to you for being in the study? 
• We expect the procedure to make the pain in your eye less for a period of three to six 
months. Note that we do not expect the pain to go away completely but only to 
become less. 
• There is a chance that the procedure could improve your vision for a while as well 
• You will be helping us to understand your condition better which may help other 
patients in future 
What are the risks of this study? 
• The biggest risk is that you could get an eye infection called “Infective keratitis” after 
the procedure. We will do everything possible to prevent this, but if you do get this 
infection you will need to be admitted to the hospital for treatment. Treatment usually 
means drops onto the eye every hour. If the drops don’t work you might need to go 
for an operation. 
• The other risk is that we expect that the procedure will make your pain worse for the 
first week after the procedure while the eye is healing 
• There is also a chance that the procedure might not actually decrease your pain. 
Because this is an experimental procedure we cannot be sure that it is going to work. 
What happens if you get hurt taking part in this study?  
• This research study is covered by an insurance policy taken out by the 




• If you suffer a bodily injury because you are taking part in the study the 
insurer will pay for all reasonable medical costs required to treat your bodily 
injury, according to the SA Good Clinical Practice Guidelines 2006 (or latest 
version), which are based on the Association of the British Pharmaceutical 
Industry Guidelines. The insurer will pay without you having to prove that the 
research was responsible for your bodily injury.  
• You may ask the study doctor for a copy of these guidelines. 
• The insurer will not pay for harm if, during the study, you:  
o Use medicines or other substances that are not allowed 
o Do not follow the study doctor’s instructions 
o Do not tell the study doctor that you have a bad side effect from 
the study procedure or medicines 
o Do not take reasonable care of yourself and your study medicines 
• If you are harmed and the insurer pays for the necessary medical costs, 
usually you will be asked to accept that insurance payment as full settlement 
of the claim for medical costs. However, accepting this offer of insurance 
cover does not mean you give up your right to make a separate claim for 
other losses based on negligence, in a South African court.  
• It is important to follow the study doctor’s instructions and to report 
straightaway if you have a side effect from the study medicine. 
What other choices do you have? 
• There are drops which you can use which might help make your pain less, but often 
they don’t help when the condition has become advanced. 
• There are other surgery procedures which can be done but we don’t use them here 
at Groote Schuur because they haven’t been shown to work as well as we would like. 
• The best treatment for this condition is to replace the area of the eye that is affected 
with the same part from another person who has died. This is called a “Corneal 
transplant”. If you want to have it done at Groote Schuur you will be put on a waiting 
list. If you want to have it done sooner you can have it done at a private eye 
specialist. 
What will happen when the study is over? 
• You and the doctor will discuss how your condition is doing and decide on what 
treatment will be best for you afterwards. 




Who will see the information which is collected about you during the study? 
• Only the doctors involved in the study will see the information collected but the 
results of the study will be made available to the public 
Who do I contact if I have any questions, comments, complaints or problems during the 
study? 
• You can contact Dr McClunan via cell: 0846047600 or E-mail dae.mcc@gmail.com 
• Alternatively you can visit the UCT Human Research Ethics Committee at the Old 
Main Building of Groote Schuur Hospital, Floor E52, Room 23 or  phone: 021 406 
6626 
• If you have an emergency please go to the Groote Schuur emergency area to be 

















Patient full name and signature
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Appendix B: Data collection pro-forma 
 
Day of debridement Code 
Date /       /2016 - 
Phone number  - 
Age years - 
Sex Male / Female  
Race African / Mixed / Indian / Asian / White  
Diagnosis Pseudo / Fuchs / Graft / Trauma 
       Other: 
 
Other important findings 
 
  
Duration of symptoms                Years                      Months - 
Unilateral/bilateral Right / Left / Bilateral  
Eye with most discomfort Right / Left  
Current treatment BCL / Lubricants / Hypertonic Saline  
Exclusion criteria 
Specify 
No / Yes  
Snellen visual acuity   
Pain score /10  
Micro bullae / Macro bullae  Micro / Macro  
Corneal transparency 1  /  2  /  3  /  4  
Goldmann intra-ocular pressure mmHg  
Central corneal thickness µm - 
Anterior segment photo taken Yes / No  
Discharge medication Antibiotic drops / Paracetamol - 
Follow up date /       / 2016 - 









Follow up appointment: 10 days Code 
Folder number  - 
Date /        / 2016 - 
Patient used antibiotic drops Yes / No  
Average pain score  /10  
BCL  in situ Yes / No  
BCL removed Yes  
Snellen visual acuity   
Infective keratitis Yes / No  
Micro bullae / Macro bullae  Micro / Macro  
Corneal transparency 1  /  2  /  3  /  4  
Anterior segment photo taken Yes / No  
CCT   
Discharge medication SpersadexCo   Other: - 





Follow up appointment: 1 month Code 
Folder number  - 
Date /        / 2016 - 
Patient used antibiotic/steroid drops Yes / No  
Average pain score  /10  
Snellen visual acuity   
Infective keratitis Yes / No  
Micro bullae / Macro bullae  Micro / Macro  
Corneal transparency 1  /  2  /  3  /  4  
Anterior segment photo taken Yes / No  
CCT   
Discharge medication Nil                                   Other: - 






Follow up appointment: 2 months Code 
Folder number  - 
Date /        / 2016 - 
Average pain score  /10  
Snellen visual acuity   
Infective keratitis Yes / No  
Micro bullae / Macro bullae  Micro / Macro  
Corneal transparency 1  /  2  /  3  /  4  
Anterior segment photo taken Yes / No  
CCT   
Discharge medication Nil 
   Other: 
- 





Follow up appointment: 3 months Code 
Folder number  - 
Date /        / 2016 - 
Average pain score  /10  
Snellen visual acuity   
Infective keratitis Yes / No  
Micro bullae / Macro bullae  Micro / Macro  
Corneal transparency 1  /  2  /  3  /  4  
Anterior segment photo taken Yes / No  
CCT   
Discharge medication Nil 
   Other: 
- 








Follow up appointment: 6 months Code 
Folder number  - 
Date /        / 2016 - 
Average pain score  /10  
Snellen visual acuity   
Infective keratitis Yes / No  
Micro bullae / Macro bullae  Micro / Macro  
Corneal transparency 1  /  2  /  3  /  4  
Anterior segment photo taken Yes / No  
CCT   



















Appendix C: Instructions to authors 
Journal of choice: Cornea 
See instructions for authors at http://edmgr.ovid.com/cornea/accounts/ifauth.htm.  
For the purpose of this thesis: 
• The title page and abstract have been omitted 
• Figures and tables are included in the text  
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